Clicky

Dr Irshad Khan and Partners – Library – Behind the Headlines

HHV-6 being released from a lymphocyte Three words you don’t want to hear are ‘inherited herpes virus’. A new study suggests a novel form of immunotherapy could be effective for treating some cases of advanced skin cancer… These include binding and retention of MHC I chains in the endoplasmic reticulum, dislocation of class I chains from the ER, inhibition of the peptide transporter (TAP) involved in antigen presentation, and shunting of newly assembled chains to lysosomes. Thus what role DC infection plays in the pathogenesis of persistent infections is unclear. Curtis Brandt, a professor of medical microbiology and ophthalmology, said: “The viral strains sort exactly as you would predict based on sequencing of human genomes. 7-aza-Trp residues at either position showed a emission spectral shift in the presence of TBP (but not TFIIB), indicating a change to a more hydrophobic environment. It is injected directly into the tumour and causes the production of a chemical called granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates an immune response to fight the cancer.

It also improved overall survival, but this only just reached statistical significance, meaning we can have less confidence in this effect. It usually strikes when the calves are between 1 and 4 years old. Macrophages were seen to contact acutely infected epithelial cells, and cre/lox-based virus tagging showed that almost all the virus recovered from lymphoid tissue had passed through lysM+ and CD11c+ myeloid cells. CMVs harbor large double-stranded DNA genomes of about 230 kbp (7, 32). It is also not known whether the treatment would work for other types of cancer. The quality of the reporting of this study is somewhat patchy. Moreover, the PCLγ2 cSH2 domain, when overexpressed in KSHV infected endothelial cells, reduces the angiogenesis and invasiveness induced by the virus.

Impaired cellular immunity plays a critical role in allowing KSHV replication, but the physiological stimuli that positively induce lytic gene expression are poorly understood. Injecting a treatment that produces GM-CSF within a tumour should, in theory, boost the immune response to fight the tumour. Yan Huang, Alberto Hidalgo-Bravo, Enjie Zhang, Victoria E. GM-CSF injections are given under the skin, rather than directly into a tumour. The striking increase in the frequency of KS in KSHV-infected individuals with HIV-mediated immunodeficiency (5) suggested to us that T cells may play a central role in host control of KSHV infection. However several persistent viruses, which might be expected to limit their exposure to host immunity, efficiently infect DCs [7]–[10]. Treatment was continued regardless of disease progression for 24 weeks, and after 24 weeks continued until there was disease progression, lack of response, remission or intolerability.

Later, VP16 was shown to directly interact with another basal transcription factor, TFIIB(18), although there is some discrepancy about the specificity of this interaction(11, 13, 19). The main outcome was disease response rate, defined as complete or partial response that started within the first 12 months and lasted continuously for at least six months. Response was measured through clinical assessment of the visible tumour and body scans. Disease response rate was significantly better in people given T-VEC (16.3%) compared with those given GM-CSF (2.1%). Epstein-Barr virus (EBV) infects B cells better than epithelial cells in vitro, and prominently colonizes tonsillar B cells during acute infectious mononucleosis [1]. To this end, the MCMV M50 gene product was chosen for detailed structure-function analysis. Average time to treatment failure was significantly longer in the T-VEC group (8.2 months) than in the GM-CSF group (2.9 months).

Average survival was 23.3 months with T-VEC, compared with 18.9 months with GM-CSF. For both K15P and M a mRNA comprising all eight exons is the most strongly expressed transcript and encodes a protein of 12 predicted transmembrane domains and a cytoplasmic tail involved in signalling. Norepinephrine and PKA modulating agents were diluted in phosphate-buffered saline and added to cultures in volumes ≤1% of total culture volume. Cellulitis was the only more serious side effect, occurring in a larger proportion of the T-VEC group. The trial has various strengths, including its large sample size, analysis by intention to treat, and blinding of assessors to treatment assignment, which should have reduced the risk of bias. It demonstrated that, overall, significantly more people responded to treatment with T-VEC than GM-CSF injections. The HA and Flag epitope tags were inserted by PCR downstream of the first methionine of each ORF; the resulting HA-K3 and Flag-K5 were cloned into pCR3.1 vector.

And while DNA from lung-inoculated, replication-deficient MuHV-4 has been found associated with B cells [25], [26], viral genome-positive B cells did not reach the spleen, so whether the detected DNA was a viable primary infection or merely adsorbed debris was unclear. However, GM-CSF is not used as a treatment for advanced melanoma. Recently, several groups reported that Trp analogs (5-hydroxytryptophan or 7-azatryptophan) can be successfully incorporated into proteins by using Trp auxotrophic Escherichia coli strains and supplementing the growth media with the relevant Trp analog(27, 28, 29). The treatment has not been shown to “cure” melanoma. Most of the people in this study passed away during the two years of follow-up, but the people receiving T-VEC generally lived slightly longer. The treatment is a genetically engineered derivative of herpes simplex type 1 virus. MuHV-4 depends on heparan sulfate (HS) to infect adherent cells [24], and poor B cell infection by MuHV-4 and KSHV has been attributed to B cells lacking HS [25].

The 1.3-kbp AflIII-DraIII fragment of pCR3 was cloned into the EcoRV and BamHI sites of pOriR6K-zeo, generating pOriR6K-zeo-ie. It is not known whether this treatment could only have potential for the treatment of advanced melanoma, or whether it could have other potential uses for other types of cancer. As with most conditions, prevention is more effective than cure when it comes to melanoma. Invasion assay in KSHV infected HuAR2T transfected with the indicated siRNAs, forty-eight hours after the induction of the lytic cycle (indicated with +).

Dr Irshad Khan and Partners – Library – Behind the Headlines

Lawrence CM, Lonsdale-Eccles A. It maintains self-esteem, comfort, and the person’s ability to communicate, socialise, and enjoy food and drinks. The Daily Mail reported that the cold sore virus “may be one of the main causes of Alzheimer’s disease”. The newspaper said researchers have found that the herpes simplex virus 1 (HSV1) could be present in up to 60% of Alzheimer’s cases. There may be just one lesion or many on the trunk and limbs. The news coverage could be interpreted to mean the research found that people with cold sores will develop Alzheimer’s or that infection with the cold sore virus alone could cause Alzheimer’s. If the infection reoccurs, symptoms are usually milder.

It found an association between HSV1 in the brain and brain plaques in Alzheimer’s brains and normal elderly brains. They saved Darren’s life. after treatment is stopped at day 3) and tends to resolve by day 14. They have previously suggested that the virus would most likely work in combination with genetic factors to be causal for Alzheimer’s disease. Larger studies would be needed to better establish this association and to find practical applications to prevent Alzheimer’s. At present, the evidence does not support immunisation or taking antiviral treatments in the hope of preventing Alzheimer’s disease. This research was conducted by Doctors Wozniak, Mee and Itzhaki and supported by a grant from the Alzheimer’s Society and from the Henry Smith Charity.


It was published in the peer-reviewed Journal of Pathology. Patients should be encouraged to spit out excess toothpaste after brushing. It was a pathology study in the laboratory using brain samples from dead bodies. While there are several biological reasons why the two may be linked, these were not explored in this study. This purpuric rash is palpable and may also blister. The theory underpinning the study was that there could be a link between HSV 1 and Alzheimer’s. This is because HSV1 is associated with a rare brain disorder called herpes simplex encephalitis.

This condition affects the parts of the brain that are also most affected by Alzheimer’s disease. The researchers obtained brain samples from six deceased people with Alzheimer’s and five deceased elderly normal subjects from the South West Dementia Brain Bank in Bristol.They used a technique known as in situ PCR to detect whether there was any evidence of HSV1 DNA in the brain samples. PCR (polymerase chain reaction) as a method is a technique used to replicate DNA molecules from cells in large quantities so that they can be investigated more easily. In situ PCR is an application of PCR techniques that amplifies the genetic material within cells – rather than extracting it first. In situ PCR increases the number of copies so that DNA can be visualised within the tissue, allowing researchers to precisely visualise and locate a specific type of DNA within tissue.The researchers were interested in whether there was a link (in terms of proximity) between HSV1 and brain plaques in their samples. Brain plaques are clumps of protein deposits found in the brains of people with Alzheimer’s and are a characteristic of the disease. The plaques are also present in the brains of elderly people without Alzheimer’s, but are found in smaller numbers.

The researchers detected HSV1 DNA in all six samples from Alzheimer’s sufferers and in the five elderly normal people. Patients may be advised to avoid antipyretic analgesics (paracetamol, aspirin) if at risk of neutropenia (can mask fever due to sepsis). HSV1 was present in 90% of the brain plaques found in Alzheimer’s patients, and 80% of the brain plaques found in normal patients. The researchers say that these findings, “suggest that the virus might be a cause of plaque formation in many of these subjects”. Commonest causative agents include the anticonvulsants, allopurinol, minocycline and sulphasalazine and the eruption may take several weeks to develop. This means that more of the viral DNA was associated with plaques in Alzheimer’s disease compared with normal people. The researchers conclude that while “association does not prove causality”, alternative explanations for the presence of HSV1 in brain plaques are unlikely.

They discuss these alternative explanations in some detail. In their write up, the researchers use previously published research by other groups to highlight possible differences between people who get Alzheimer’s and those who do not.They suggest  the possibility that people who do not get Alzheimer’s produce less amyloid (a substance that deposits in the brain and is implicated in the formation of brain plaques), or are better at clearing it. While the results may support the involvement of HSV1 in the formation of plaques in the brain, there is no indication from this study why some people develop Alzheimer’s while others with brain plaques and HSV1 do not. The success of using in situ PCR to investigate latent (or hidden) infections is an important finding, which will no doubt be used in future research examining the link between HSV1 and Alzheimer’s disease. This is a small laboratory study that offers preliminary results. Larger laboratory studies, and (more importantly) animal and human studies will be needed before it is known whether this avenue of research will result in a practical application for preventing Alzheimer’s.